# Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/ > **Published:** 2026-03-01T10:11:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:55-04:00 > **Clinical Summary:** Explore cannabis beverage substitution alcohol research and its impact on consumption and health outcomes in New York over five years. --- **A study presented at the 2026 International [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) Conference suggests that adults who substitute THC or CBD beverages for traditional alcohol may experience measurable differences in consumption behavior and related health outcomes. For clinicians navigating patient conversations about harm reduction and substance use, preliminary findings of this kind carry practical weight in informing shared decision-making around cannabis-based alternatives. The research adds to a growing but still limited body of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), and its observational design means causality cannot yet be established.** This report is relevant to ongoing discussions in [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and medical cannabis evidence-based care. ## Study Design and Findings The research, presented at the 2026 International [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) Conference, examined adults who reported substituting THC- or CBD-containing beverages for conventional alcoholic drinks. The observational design tracked differences in consumption behavior and associated health outcomes between those using cannabis-based alternatives and those continuing traditional alcohol use. While the conference presentation format limits the depth of methodological detail currently available, the study contributes a meaningful data point to the field of **endocannabinoid system clinical research**, particularly as cannabis beverage products become more widely accessible in regulated markets. Participants who made the substitution showed measurable differences in outcomes related to consumption patterns, though the specific metrics and magnitude of effect have not been fully detailed in available reporting. Because the study is observational in design, no causal relationship between cannabis beverage use and health outcomes can be drawn from these findings alone. ## Clinical Implications For clinicians engaged in harm reduction conversations, preliminary data of this nature can inform the framing of shared decision-making discussions with patients who are independently considering cannabis-based alternatives to alcohol. The findings do not yet meet the evidentiary threshold required to support formal clinical recommendations, and practitioners should situate them within the broader context of **medical cannabis evidence-based care**, which continues to evolve as regulatory and research infrastructure expands. ** Related Reading ** - [Cannabis basics overview](https://cedclinic.com/cannabis-basics-overview/) - [Cannabis research library](https://cedclinic.com/resources/cannabis-literature-library/) - [Medical cannabis at a crossroads](https://cedclinic.com/medical-cannabis-crossroads-future-of-care/) Significant questions remain regarding population generalizability, duration of observation, and the role of individual endocannabinoid system variability in mediating any observed differences. Until more rigorously controlled *cannabis [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/)* are available, these findings are best interpreted as hypothesis-generating rather than practice-changing. Clinicians are encouraged to document patient-reported substitution behavior as part of routine substance use screening, which may help build the real-world data needed to support future prospective research. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). [www.cedclinic.com](https://cedclinic.com/about-us/meet-the-doctors/meet-dr-caplan/) Further Reading Cannabis News[Cooney introduces bill to allow selling of low-potency cannabis beverages at liquor and wine stores](https://cedclinic.com/low-dose-thc-beverages-bill-new-york/) Evidence Watch[Daily Digest 2026-03-08](https://cedclinic.com/daily-cannabis-news-digest-march-8-2026/) Cannabis Memes[College is hard lmao](https://cedclinic.com/college-is-hard-lmao/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabis-Infused%20Beverages%20as%20Alcohol%20Alternatives%3A%20New%20York%20at%20Five%20Years&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-beverage-substitution-alcohol-new-york-five-years%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-beverage-substitution-alcohol-new-york-five-years%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabis-Infused%20Beverages%20as%20Alcohol%20Alternatives%3A%20New%20York%20at%20Five%20Years%20https%3A%2F%2Fcedclinic.com%2Fcannabis-beverage-substitution-alcohol-new-york-five-years%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).